Deborah Elstein
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Deborah Elstein has a total of 236 co-authors. Here are the top co-authors by number of shared publications:
Ari Zimran
Gaucher Clinic and Department of Orthopedic Surgery, Shaare Zedek Medical Center, Affiliated with the Hadassah-Hebrew University Medical School, Jerusalem, Israel
32 shared publications- Ari Zimran
Gaucher Unit, The Eisenberg R&D Authority, Shaare Zedek Medical Center, Jerusalem 9103102, Israel
23 shared publications Gheona Altarescu
Medical Genetics Institute, Shaare Zedek Medical Center, Affiliated with the Hadassah-Hebrew University School of Medicine, Jerusalem, Israel
15 shared publications- Gheona Altarescu
Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel
12 shared publications Irith Hadas-Halpern
Shaare Zedek Medical Center, Affiliated to the Hadassah-Hebrew University School of Medicine, Ein Karem 91031, Israel
9 shared publicationsArnon Samueloff
Department of Obstetrics & Gynecology, Shaare Zedek Medical Center Affiliated with the Hebrew University Hadassah School of Medicine, P.O. Box 3235, 12 Bayit Street, 91031 Jerusalem, Israel
6 shared publications
Latest Publications
- 1 October 2016
- Published by Elsevier in Journal of Clinical Densitometry
- Vol. 19 (4) , 465-470
Comparison of Bone Mineral Density by Dual-Energy X-Ray Absorptiometry and Bone Strength by Speed-of-Sound Ultrasonography in Adults With Gaucher Disease
- 1 October 2016
- Published by Elsevier in Journal of Clinical Densitometry
- Vol. 19 (4) , 465-470
Comparison of Bone Mineral Density by Dual-Energy X-Ray Absorptiometry and Bone Strength by Speed-of-Sound Ultrasonography in Adults With Gaucher Disease
- 9 July 2016
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 22 (7) , 693-697
Thromboelastography as a Surrogate Marker of Perisurgical Hemostasis in Gaucher Disease
Thromboelastography (TEG) has long been available for routine monitoring of perisurgical and postpartum hemostasis, especially at point of care. The purpose of this study is to retrospectively compare TEG parameters to concomitant standard clotting test results in an unselected cohort of patients with Gaucher disease to ascertain whether TEG values are specific and sensitive enough to substitute for classic coagulation tests for decision making. This remains a cogent concern because of high incidence of thrombocytopenia in patients with Gaucher disease. Thromboelastography values were compared to concomitant platelet counts, partial thromboplastin time, international normalization ratio, and plasma fibrinogen. Demographic characteristics were collected from patients’ files. There were 22 patients with Gaucher disease (2 children; 12.5%) for whom there were 24 TEG results at the same time as classic coagulation test results and 30% performed platelet function tests. The current study shows linear and/or monotonic relationships between platelet counts and several TEG values that were significant over a range of platelet counts including severe thrombocytopenia. The fibrinogen component, correlating only with the rate of clot lysis, played a lesser role. Based on these preliminary results albeit in a small cohort with only 1 case of hemorrhage, there is putative support for the intention to treat patients with Gaucher disease based on TEG results using the same TEG protocol as for other patients undergoing comparable procedures in our institution.
- 9 July 2016
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 22 (7) , 693-697
Thromboelastography as a Surrogate Marker of Perisurgical Hemostasis in Gaucher Disease
Thromboelastography (TEG) has long been available for routine monitoring of perisurgical and postpartum hemostasis, especially at point of care. The purpose of this study is to retrospectively compare TEG parameters to concomitant standard clotting test results in an unselected cohort of patients with Gaucher disease to ascertain whether TEG values are specific and sensitive enough to substitute for classic coagulation tests for decision making. This remains a cogent concern because of high incidence of thrombocytopenia in patients with Gaucher disease. Thromboelastography values were compared to concomitant platelet counts, partial thromboplastin time, international normalization ratio, and plasma fibrinogen. Demographic characteristics were collected from patients’ files. There were 22 patients with Gaucher disease (2 children; 12.5%) for whom there were 24 TEG results at the same time as classic coagulation test results and 30% performed platelet function tests. The current study shows linear and/or monotonic relationships between platelet counts and several TEG values that were significant over a range of platelet counts including severe thrombocytopenia. The fibrinogen component, correlating only with the rate of clot lysis, played a lesser role. Based on these preliminary results albeit in a small cohort with only 1 case of hemorrhage, there is putative support for the intention to treat patients with Gaucher disease based on TEG results using the same TEG protocol as for other patients undergoing comparable procedures in our institution.
- 1 February 2016
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 117 (2) , S45
Children with type 1 Gaucher disease: Changing profiles in the 21st century
- 1 February 2016
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 117 (2) , S45
Children with type 1 Gaucher disease: Changing profiles in the 21st century
- 14 September 2015
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 5 (3) , 525-531
Color Discrimination in Patients with Gaucher Disease and Parkinson Disease
Background: Poor color discrimination among patients with Parkinson disease (PD) has long been recognized. It has been shown that carrying one or two mutations in the β-glucocerebrosidase gene (GBA) for the autosomal disease Gaucher disease (GD), as
- 14 September 2015
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 5 (3) , 525-531
Color Discrimination in Patients with Gaucher Disease and Parkinson Disease
Background: Poor color discrimination among patients with Parkinson disease (PD) has long been recognized. It has been shown that carrying one or two mutations in the β-glucocerebrosidase gene (GBA) for the autosomal disease Gaucher disease (GD), as
- Open Access
- 16 March 2015
- Published by Wiley in American Journal of Hematology
- Vol. 90 (7) , 592-597
Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease
Gaucher disease (GD) is a lysosomal storage disorder; symptomatic patients with type 1 GD need long‐term disease‐specific therapy of which the standard of care has been enzyme replacement therapy (ERT). Thirty‐eight of 40 patients (aged 9–71 years) clinically stable on ERT with imiglucerase, safely switched to a comparable dose of velaglucerase alfa (units/kg) during TKT034, a 12‐month, open‐label clinical study, and for 10–50 months in an extension study. The most common adverse events (AEs) judged to be drug‐related in the extension were fatigue and bone pain. No drug‐related serious AEs were reported. No AEs led to study withdrawal. At 24 months from baseline (baseline being TKT034 week 0), patients had generally stable hemoglobin, platelet, spleen, liver, and bone density parameters. Nevertheless, dose adjustment based on the achievement of therapeutic goals was permitted, and 10 patients, including seven patients who had platelet counts 9/L at baseline, were given at least one 15 U/kg‐dose increase during the extension. Trends indicative of improvement in platelet count and spleen volume, and decreasing levels of GD biomarkers, chitotriosidase and CCL18, were observed. Immunogenicity was seen in one patient positive for anti‐imiglucerase antibodies at baseline. This patient tested positive for anti‐velaglucerase alfa antibodies in TKT034, with low antibody concentrations, and throughout the extension study; however, the patient continued to receive velaglucerase alfa without clinical deterioration. In conclusion, clinically stable patients can be switched from imiglucerase to velaglucerase alfa ERT and maintain or achieve good therapeutic outcomes. Am. J. Hematol. 90:592–597, 2015.
- 16 March 2015
- Published by Wiley in American Journal of Hematology
- Vol. 90 (7) , 592-597
Open AccessSafety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease
Gaucher disease (GD) is a lysosomal storage disorder; symptomatic patients with type 1 GD need long‐term disease‐specific therapy of which the standard of care has been enzyme replacement therapy (ERT). Thirty‐eight of 40 patients (aged 9–71 years) clinically stable on ERT with imiglucerase, safely switched to a comparable dose of velaglucerase alfa (units/kg) during TKT034, a 12‐month, open‐label clinical study, and for 10–50 months in an extension study. The most common adverse events (AEs) judged to be drug‐related in the extension were fatigue and bone pain. No drug‐related serious AEs were reported. No AEs led to study withdrawal. At 24 months from baseline (baseline being TKT034 week 0), patients had generally stable hemoglobin, platelet, spleen, liver, and bone density parameters. Nevertheless, dose adjustment based on the achievement of therapeutic goals was permitted, and 10 patients, including seven patients who had platelet counts 9/L at baseline, were given at least one 15 U/kg‐dose increase during the extension. Trends indicative of improvement in platelet count and spleen volume, and decreasing levels of GD biomarkers, chitotriosidase and CCL18, were observed. Immunogenicity was seen in one patient positive for anti‐imiglucerase antibodies at baseline. This patient tested positive for anti‐velaglucerase alfa antibodies in TKT034, with low antibody concentrations, and throughout the extension study; however, the patient continued to receive velaglucerase alfa without clinical deterioration. In conclusion, clinically stable patients can be switched from imiglucerase to velaglucerase alfa ERT and maintain or achieve good therapeutic outcomes. Am. J. Hematol. 90:592–597, 2015.
- 1 March 2015
- Published by Elsevier in Best Practice & Research Clinical Endocrinology & Metabolism
- Vol. 29 (2) , 249-259
The emergence of Parkinson disease among patients with Gaucher disease
- 1 March 2015
- Published by Elsevier in Best Practice & Research Clinical Endocrinology & Metabolism
- Vol. 29 (2) , 249-259
The emergence of Parkinson disease among patients with Gaucher disease
- 1 February 2015
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 114 (2) , S129-S130
Markers of bone turnover in patients with type 1 Gaucher disease receiving long-term velaglucerase alfa enzyme replacement therapy
- 1 February 2015
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 114 (2) , S129-S130
Markers of bone turnover in patients with type 1 Gaucher disease receiving long-term velaglucerase alfa enzyme replacement therapy
- 1 February 2015
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 114 (2) , S41-S42
The need for disease-specific patient-reported outcome measures for lysosomal disorders
- 1 February 2015
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 114 (2) , S41-S42
The need for disease-specific patient-reported outcome measures for lysosomal disorders
- Open Access
- 1 January 2015
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 54 (1) , 9-16
Safety and efficacy of two dose levels of taliglucerase alfa in pediatric patients with Gaucher disease
- 1 January 2015
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 54 (1) , 9-16
Open AccessSafety and efficacy of two dose levels of taliglucerase alfa in pediatric patients with Gaucher disease